The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Open accessAbstract
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T cells (TCR T). Unlike chimeric antigen receptors (CARs), TCRs recognize HLA-presented peptides derived from proteins of all cellular compartments. The use of TCR T cells for adoptive cellular therapies (ACT) has gained increased attention, especially as efforts to treat solid cancers with ACTs have intensified. In this review, we describe the differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs. We describe the classes of cancer antigens recognized by current TCR T therapies and discuss both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation. Finally, we review the current landscape of clinical trials for TCR T therapy and discuss what these current results indicate for the development of future engineered TCR approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Vasileiou, S., Lulla, P., Tzannou, I., Watanabe, A., Kuvalekar, M., Callejas, W. L., Bilgi, M., Wang, T., Wu, M., Kamble, R. T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02224 · Cited by 46
Campillo-Davó, D., Fujiki, F., den Bergh, J. M. J. V., Reu, H. D., Smits, E., Goossens, H., Sugiyama, H., Lion, E., Berneman, Z. N., & Tendeloo, V. F. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02503 · Cited by 44
Vlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2222 · Cited by 41
Campo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S. P., Vales, Á., Paschen, A., Ward, S., Ruiz‐Cabello, F., González‐Aseguinolaza, G., & Garrido, F. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02276.x · Cited by 40
Lulla, P. D., Tzannou, I., Vasileiou, S., Carrum, G., Ramos, C. A., Kamble, R., Wang, T., Wu, M., Bilgi, M., Gee, A. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3339 · Cited by 40
Ponterio, E., Maria, R. D., & Haas, T. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565631 · Cited by 40
Liu, Q., Hao, C., Su, P., & Shi, J. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902998679 · Cited by 39
Ma, W., Vigneron, N., Chapiro, J., Stroobant, V., Germeau, C., Boon, T., Coulie, P. G., & den Eynde, B. J. V. (2011) · International Journal of Cancer · doi:10.1002/ijc.25911 · Cited by 39
Luo, X., Cui, H., Cai, L., Zhu, W., Yang, W.-C., Patrick, M., Zhu, S., Huang, J., Yao, X., Yao, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00623 · Cited by 37
Kunert, A., van Brakel, M., van Steenbergen‐Langeveld, S., da Silva, M., Coulie, P. G., Lamers, C., Sleijfer, S., & Debets, R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502024 · Cited by 34
A Novel Murine T-Cell Receptor Targeting NY-ESO-1
Rosati, S. F., Parkhurst, M. R., Hong, Y. K., Zheng, Z., Feldman, S. A., Rao, M., Abate‐Daga, D., Beard, R. E., Xu, H., Black, M. A., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000019 · Cited by 31
Evaluation of cyclin A1–specific T cells as a potential treatment for acute myeloid leukemia
Leung, W. K., Workineh, A. G., Mukhi, S., Tzannou, I., Brenner, D., Watanabe, N., Leen, A. M., & Lulla, P. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000715 · Cited by 30
Hu, Z., Zhu, L., Wang, J., Wan, Y., Yuan, S., Chen, J., Ding, X., Qiu, C., Zhang, X., Qiu, C., et al. (2017) · Scientific Reports · doi:10.1038/srep41558 · Cited by 13
Cellular therapy against public neoantigens
Armistead, P. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126116 · Cited by 12
Generation of Human T Cell Clones
Mariotti, S., & Nisini, R. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-527-9_6 · Cited by 11
Immunogenicity of a public neoantigen derived from mutated PIK3CAPreprint
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.08.439061 · Cited by 3
Hiscox, M. J., Wasmuth, A., Williams, C. L., Foot, J. N., Wiedermann, G. E., Fadda, V., Boiani, S., Cornforth, T. V., Wikiert, K. A., Bruton, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301175 · Cited by 1
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“Such a strategy deflects T cell specificity to recognize specific antigens in the context of HLA presentation in any subcellular compartment [109].”
Background
Metadata
- Authors
- Shafer, P., Kelly, L. M., & Hoyos, V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-03-03
- Volume
- 13
- Pages
- 835762-835762
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4214927528
- Cited by
- 270
- References
- 217
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.